Cartesian Therapeutics Inc. logo

Cartesian Therapeutics Inc.

RNAC | NASDAQ
Chart Builder DCF Calculator
$8.13
+$0.19 (+2.39%)
Sep 22, 2026, 2:34 PM ET · Market open

Market Data

Market Cap
$233.29M
Enterprise Value
$96.69M
Beta
0.62
Average Volume
230.3K
Shares Outstanding (Diluted)
29.86M
Shares Change YoY
12.91%
Institutional Ownership
26.63%
Exchange
NASDAQ
ISIN
US8162123025

Price Performance

Price Change 1M
-22.0%
Price Change 3M
-22.0%
Price Change 6M
27.0%
Price Change YTD
17.5%
Price Change 1Y
-20.9%
Price Change 3Y
-75.0%
Price Change 5Y
-93.9%
1M CAGR (ann.)
-10.3%
1Y CAGR (ann.)
-23.0%
5Y CAGR (ann.)
-42.8%
All-Time CAGR
-32.1%

Valuation

PE Ratio
-1.36
Forward PE
N/A
PEG Ratio
0.01
Forward PEG
-0.03
PS Ratio
157.95
Forward PS
699.90
PB Ratio
-1.86
P/FCF Ratio
-2.98
P/Adj. FCF Ratio
-2.67
P/OCF Ratio
-3.08
EV/Sales
65.46
EV/EBIT
-0.60
EV/EBITDA
-0.61
EV/FCF
-1.24
Earnings Yield
-73.5%
FCF Yield
-33.5%
Adj. FCF Yield
-37.5%

Financial Health

Net Cash
$136.6M
Total Debt
$11M
Cash & Short-Term Investments
$147.61M
Total Assets
$318.63M
Current Ratio
7.48
Quick Ratio
7.48
Debt / Equity Ratio
-0.51
Debt / EBITDA
-0.07
Debt / FCF
-0.14
OCF / Debt
-6.91
Interest Coverage
-115.80
Altman Z-Score
-4.55
Piotroski F-Score
2

Margins & Profitability

Gross Profit Margin
-766.4%
Operating Profit Margin
-6679.7%
EBITDA Margin
-10670.5%
Net Profit Margin
-10422.5%
FCF Margin
-5291.5%
Adj. FCF Margin
-5917.1%
SBC / Revenue
625.6%
SBC Impact (per share)
-11.8%

Returns

Return on Assets
-48.3%
Return on Equity
141.4%
Return on Invested Capital
-30.8%
Return on Capital Employed
-33.1%
Return on Tangible Assets
-87.2%

Historical Growth (CAGR)

Revenue CAGR 3Y
-68.8%
Revenue CAGR 5Y
-50.0%
Revenue CAGR 10Y
-15.4%
EPS CAGR 3Y
117.8%
EPS CAGR 5Y
-16.3%
EPS CAGR 10Y
26.3%
FCF CAGR 3Y
-10.4%
FCF CAGR 5Y
-7.0%
FCF CAGR 10Y
-6.0%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
10
EPS Growth Next 3Y
13.2%
Revenue Growth Next 3Y
289.3%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
-$1.02
EPS Growth Est (next Q)
-26.1%
Revenue Est (next Q)
$180K
Revenue Growth Est (next Q)
-60.2%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$25
Price Target Upside
214.9%

Cash Flow

Operating Cash Flow
$-76.07M
Free Cash Flow
$-78.16M
Adj. Free Cash Flow
$-87.4M
FCF Per Share
-$2.65
OCF Per Share
-$2.58
OCF/S Ratio
-5150.5%

Income Statement

Revenue
$1.48M
Gross Profit
$-11.32M
Operating Income
$-98.66M
EBITDA
$-157.6M
Net Income
$-153.94M
EPS (Diluted)
-$5.84
Revenue / Employee
$19.69K
Profit / Employee
$-2.05M
Employees
75

© 2026 bestshares.com. All rights reserved.